Targeted dual degradation of GPC-3 and VEGFR with multivalent DNA nanoflower-based LYTACs for hepatocellular carcinoma therapy.
While targeted therapies for hepatocellular carcinoma (HCC) have advanced, their clinical benefits remain constrained by limited efficacy, off-target toxicity, and the frequent emergence of drug resistance and recurrence. To address these challenges, we developed a multivalent DNA nanoflower-based dual-targeting LYTAC...